newsfilter
← Latest News
Business Wire·

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – Anticipated cost savings,